In addition to p62, two new Keap1-binding proteins, aPKCι (atypical protein kinase Cι) and PALB2 (partner and localizer of BRCA2) have been reported to inhibit ROS and promote tumor growth and drug resistance by inducing Nrf2 accumulation, nuclear translocation, and activation (Table 1) [41, 42]. Here, NFE2L2 is linked to neoplasm.